Champions Oncology, Inc.
CSBR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000771856
No open-market purchases or sales by Champions Oncology, Inc. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $36.3M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Champions Oncology, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 32 | 32 | 0 |
| Shares | 6.22M | 6.24M | +16.8K (+0.3%) |
| Value | $49.8M | $46.8M | −$3.02M (−6.1%) |
New holders (3)
Institutions that held Champions Oncology, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna Fundamental Investments, LLC | 23,100 | $173.0K | 0.00% |
| Ergoteles LLC | 13,937 | $105.0K | 0.00% |
| Barclays PLC | 1,342 | $10.0K | 0.00% |
Sold out (3)
Institutions that held Champions Oncology, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| ClariVest Asset Management LLC | 48,200 | $386.0K |
| UBS Group AG | 2,000 | $16.0K |
| Total Clarity Wealth Management, Inc. | 937 | $7.00K |